Intensive Cytarabine‑Containing Immunochemotherapy Followed by Autologous Stem Cell Transplantation for Young, Fit Mantle‑Cell Lymphoma Patients with Marrow Infiltration

Immediate Treatment Approach

Initiate therapy at diagnosis in all symptomatic patients or those with high tumor burden—including marrow infiltration causing pancytopenia—because delayed treatment worsens outcomes. Level III evidence. 2, 4, 5
Pancytopenia resulting from disease infiltration is a marker of high tumor burden and mandates immediate treatment rather than observation. Level III evidence. 6

Cytarabine‑containing induction significantly prolongs median time to treatment failure versus non‑cytarabine regimens (P = 0.038) in a randomized trial. Level I evidence. 1, 3, 7
The intensive strategy that incorporates autologous stem‑cell transplantation (ASCT) yields higher overall response and survival rates in fit patients. Level I evidence. 1, 2, 8

Regimen options (all include high‑dose cytarabine):

Alternating R‑CHOP / R‑DHAP. Level II evidence. 1, 3
R‑hyper‑CVAD (alternating hyper‑fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone with high‑dose methotrexate/cytarabine); feasibility may be limited by toxicity. Level II evidence. 1, 7, 9
Nordic‑type protocols that incorporate high‑dose cytarabine. Level II evidence. 1, 3
Induction with high‑dose cytarabine alone provides insufficient response rates and should be avoided. Level I evidence. 1, 3, 7

ASCT consolidation is recommended for young, fit patients because it independently improves response and survival, regardless of rituximab use. Level I, Grade B evidence. 1, 2, 8
Adding total‑body irradiation (TBI) before ASCT benefits only patients who achieve a partial response; it offers no advantage for those in complete response. Level II evidence. 1, 3

Rituximab maintenance after R‑CHOP markedly improves progression‑free survival (PFS) and overall survival (OS). Level I, Grade A evidence. 1, 2, 8
Systematic meta‑analyses confirm that rituximab maintenance also enhances PFS across multiple studies. Level I evidence. 1, 3

TP53 mutations are associated with poorer responses to both induction chemotherapy and ASCT. Level II evidence. 10
For TP53‑mutated patients, BTK‑inhibitor‑based combinations are recommended:
- Ibrutinib plus high‑dose cytarabine‑based chemo‑immunotherapy. Level II evidence. 10
- Zanubrutinib + obinutuzumab + venetoclax, achieving ~96 % overall response rate and ~88 % complete remission in this subgroup. Level II evidence. 10
Standard ASCT provides limited benefit in TP53‑mutated disease; integration of novel agents is essential. Level II evidence. 10

Administer granulocyte‑colony stimulating factor (G‑CSF) as needed for neutropenia. Level III evidence. 6
Provide red‑cell and platelet transfusions for anemia and thrombocytopenia. Level III evidence. 6
Use antimicrobial prophylaxis during periods of neutropenia to prevent infections. Level III evidence. 5
Monitor closely for tumor‑lysis syndrome given the high tumor burden. Level III evidence. 6